The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
Open accessAbstract
Thiazolidinedione derivatives are antidiabetic agents that increase the insulin sensitivity of target tissues in animal models of non-insulin-dependent diabetes mellitus. In vitro, thiazolidinediones promote adipocyte differentiation of preadipocyte and mesenchymal stem cell lines; however, the molecular basis for this adipogenic effect has remained unclear. Here, we report that thiazolidinediones are potent and selective activators of peroxisome proliferator-activated receptor gamma (PPAR gamma), a member of the nuclear receptor superfamily recently shown to function in adipogenesis. The most potent of these agents, BRL49653, binds to PPAR gamma with a Kd of approximately 40 nM. Treatment of pluripotent C3H10T1/2 stem cells with BRL49653 results in efficient differentiation to adipocytes. These data are the first demonstration of a high affinity PPAR ligand and provide strong evidence that PPAR gamma is a molecular target for the adipogenic effects of thiazolidinediones. Furthermore, these data raise the intriguing possibility that PPAR gamma is a target for the therapeutic actions of this class of compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rosiglitazone is the most effective drug among the two approved thiazolidinediones.482”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [482]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Luckow, B., & Schütz, G. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.13.5490 · Cited by 1,701
Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Self-citationControl of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link
Hotamisligil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1271 · Cited by 1,281
Nuclear receptors enhance our understanding of transcription regulation
GREEN, S., & CHAMBON, P. (1988) · Trends in Genetics · doi:10.1016/0168-9525(88)90108-4 · Cited by 1,043
Cited by
Items 201–300 of 415
Takacs, M. L., & Abbott, B. D. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfl135 · Cited by 396
Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα
Moya-Camarena, S. Y., Heuvel, J. P. V., Blanchard, S. G., Leesnitzer, L. A., & Belury, M. A. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33384-8 · Cited by 396
Nishino, N., Tamori, Y., Tateya, S., Kawaguchi, T., Shibakusa, T., Mizunoya, W., Inoue, K., Kitazawa, R., Kitazawa, S., Matsuki, Y., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34090 · Cited by 392
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
The genetics of type 2 diabetes: what have we learned from GWAS?
Billings, L. K., & Florez, J. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05838.x · Cited by 389
PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
Murphy, G. J., & Holder, J. C. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01559-5 · Cited by 386
Retinoid X Receptor Heterodimers in the Metabolic Syndrome
Shulman, A. I., & Mangelsdorf, D. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043590 · Cited by 380
Altiok, S., Xu, M., & Spiegelman, B. M. (1997) · Genes & Development · doi:10.1101/gad.11.15.1987 · Cited by 378
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
trans-Activation of PPARα and PPARγ by Structurally Diverse Environmental Chemicals
Maloney, E. K., & Waxman, D. J. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8809 · Cited by 374
Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation
Zhou, Y.-T., Shimabukuro, M., Koyama, K., Lee, Y., Wang, M.-Y., Trieu, F., Newgard, C. B., & Unger, R. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6386 · Cited by 373
Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., & Peters, J. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 369
Wright, H. M., Clish, C. B., Mikami, T., Hauser, S., Yanagi, K., Hiramatsu, R., Serhan, C. N., & Spiegelman, B. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.3.1873 · Cited by 368
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368
Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E., & Spiegelman, B. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001297200 · Cited by 367
Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays
Kuruvilla, F. G., Shamji, A. F., Sternson, S. M., Hergenrother, P. J., & Schreiber, S. L. (2002) · Nature · doi:10.1038/416653a · Cited by 367
PPARs: diverse regulators in energy metabolism and metabolic diseases
Wang, Y.-X. (2010) · Cell Research · doi:10.1038/cr.2010.13 · Cited by 366
Differentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Alam, M. A., Subhan, N., Hossain, H., Hossain, M., Reza, H. M., Rahman, M. M., & Ullah, M. O. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0080-3 · Cited by 359
Bajaj, M., Suraamornkul, S., Piper, P., Hardies, L. J., Glass, L., Cersosimo, E., Pratipanawatr, T., Miyazaki, Y., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031315 · Cited by 358
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
Li, A. C., & Glass, C. K. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400010-jlr200 · Cited by 357
De Vos, P., Lefebvre, A. M., Miller, S. G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L. G., Staels, B., Briggs, M. R., & Auwerx, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118860 · Cited by 357
Wu, Z., Xie, Y., Morrison, R. F., Bucher, N. L., & Farmer, S. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1244 · Cited by 357
Yoon, J. C., Chickering, T. W., Rosen, E. D., Dussault, B., Qin, Y., Soukas, A., Friedman, J. M., Holmes, W. E., & Spiegelman, B. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5343-5349.2000 · Cited by 356
Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11245 · Cited by 356
PGC-1 Coactivators in Cardiac Development and Disease
Rowe, G. C., Jiang, A., & Arany, Z. (2010) · Circulation Research · doi:10.1161/circresaha.110.223818 · Cited by 355
Moore, L. B., Maglich, J. M., McKee, D. D., Wisely, B., Willson, T. M., Kliewer, S. A., Lambert, M. H., & Moore, J. T. (2002) · Molecular Endocrinology · doi:10.1210/me.16.5.977 · Cited by 355
Self-citationTranscriptional factors that promote formation of white adipose tissue
White, U. A., & Stephens, J. M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.08.023 · Cited by 355
Kanayama, T., Kobayashi, N., Mamiya, S., Nakanishi, T., & Nishikawa, J.-I. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008409 · Cited by 354
Nuttall, M. E., Patton, A. J., Olivera, D. L., Nadeau, D. P., & Gowen, M. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.3.371 · Cited by 354
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer
Fogarty, S., & Hardie, D. G. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.09.012 · Cited by 350
Steroidogenesis in the Fetal Testis and Its Susceptibility to Disruption by Exogenous Compounds
Scott, H. M., Mason, J. I., & Sharpe, R. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0016 · Cited by 350
Interdomain communication regulating ligand binding by PPAR-γ
Shao, D., Rangwala, S. M., Bailey, S. T., Krakow, S. L., Reginato, M. J., & Lazar, M. A. (1998) · Nature · doi:10.1038/24634 · Cited by 349
15d-PGJ2: The anti-inflammatory prostaglandin?
Scher, J. U., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.008 · Cited by 348
Diep, Q. N., El Mabrouk, M., Cohn, J. S., Endemann, D., Amiri, F., Virdis, A., Neves, M. F., & Schiffrin, E. L. (2002) · Circulation · doi:10.1161/01.cir.0000016049.86468.23 · Cited by 345
Li, H., Ruan, X. Z., Powis, S. H., Fernando, R., Mon, W. Y., Wheeler, D. C., Moorhead, J. F., & Varghese, Z. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00151.x · Cited by 341
Corton, J. C., Anderson, S. P., & Stauber, A. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.491 · Cited by 341
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., & Mathews, W. R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00424.2003 · Cited by 338
The role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337
Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.
Kallen, C. B., & Lazar, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5793 · Cited by 337
Barberá, M. J., Schlüter, A., Pedraza, N., Iglesias, R., Villarroya, F., & Giralt, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006246200 · Cited by 337
PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter
Fajas, L., Fruchart, J.-C., & Auwerx, J. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01273-3 · Cited by 336
Troglitazone action is independent of adipose tissue.
Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S., & Graves, R. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119839 · Cited by 334
FABP4 Attenuates PPARγ and Adipogenesis and Is Inversely Correlated With PPARγ in Adipose Tissues
Garin-Shkolnik, T., Rudich, A., Hotamisligil, G. S., & Rubinstein, M. (2014) · Diabetes · doi:10.2337/db13-0436 · Cited by 332
Marx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Koenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 331
Effect of flavonoids and Vitamin E on cyclooxygenase-2 (COX-2) transcription
O’Leary, K. A., Pascual-Tereasa, S. D., Needs, P. W., Bao, Y.-P., O’Brien, N. M., & Williamson, G. (2004) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.01.015 · Cited by 330
Lemberger, T., Saladin, R., Vázquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., Wahli, W., & Auwerx, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1764 · Cited by 329
Sarjeant, K., & Stephens, J. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008417 · Cited by 328
“In 1995 the antidiabetic thiazolidinedione drugs were shown to be high-affinity PPARg ligands (Lehmann et al. 1995).”
PPARγ is an E3 ligase that induces the degradation of NFκB/p65
Hou, Y., Moreau, F., & Chadee, K. (2012) · Nature Communications · doi:10.1038/ncomms2270 · Cited by 325
Cronet, P., Petersen, J. F. W., Folmer, R., Blomberg, N., Sjöblom, K., Karlsson, U., Lindstedt, E.-L., & Bamberg, K. (2001) · Structure · doi:10.1016/s0969-2126(01)00634-7 · Cited by 325
David, V., Martin, A., Lafage-Proust, M.-H., Malaval, L., Peyroche, S., Jones, D. B., Vico, L., & Guignandon, A. (2007) · Endocrinology · doi:10.1210/en.2006-1704 · Cited by 321
Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.372 · Cited by 320
Mascaró, C., Acosta, E., Ortiz, J. A., Marrero, P. F., Hegardt, F. G., & Haro, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8560 · Cited by 318
Burgess, H. A., Daugherty, L. E., Thatcher, T. H., Lakatos, H. F., Ray, D. M., Redonnet, M., Phipps, R. P., & Sime, P. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00383.2004 · Cited by 317
A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation
Oberfield, J. L., Collins, J. L., Holmes, C. P., Goreham, D. M., Cooper, J. P., Cobb, J. E., Lenhard, J. M., Hull-Ryde, E. A., Mohr, C. P., Blanchard, S. G., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6102 · Cited by 316
Self-citationMorrison, R. F., & Farmer, S. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17088 · Cited by 314
Petrova, T. V., Akama, K. T., & Van Eldik, L. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4668 · Cited by 314
Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.
Peraldi, P., Xu, M., & Spiegelman, B. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119715 · Cited by 314
Caron, M., Auclair, M., Vigouroux, C., Glorian, M., Forest, C., & Capeau, J. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1378 · Cited by 313
BROCKMAN, J., GUPTA, R., & DUBOIS, R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70072-1 · Cited by 313
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313
Sznaidman, M. L., Haffner, C. D., Maloney, P. R., Fivush, A., Chao, E., Goreham, D., Sierra, M. L., LeGrumelec, C., Xu, H. E., Montana, V. G., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00207-5 · Cited by 312
Self-citationHepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids
Wisely, G. B., Miller, A. B., Davis, R. G., Thornquest, A. D., Johnson, R., Spitzer, T., Sefler, A., Shearer, B., Moore, J. T., Miller, A. B., et al. (2002) · Structure · doi:10.1016/s0969-2126(02)00829-8 · Cited by 311
Self-citationPPARs: transcriptional effectors of fatty acids and their derivatives
Hihi, A. K., Michalik, L., & Wahli, W. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8467-x · Cited by 311
Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes
Gunter, M. J., & Leitzmann, M. F. (2006) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.06.011 · Cited by 310
Activation of PPARδ alters lipid metabolism in db/db mice
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01554-4 · Cited by 308
Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes
Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12864 · Cited by 308
Hormonal Signaling and Transcriptional Control of Adipocyte Differentiation
Morrison, R. F., & Farmer, S. R. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.12.3116s · Cited by 307
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
Ricote, M., Huang, J. T., Welch, J. S., & Glass, C. K. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.5.733 · Cited by 304
Transcriptional control of adipogenesis
Fajas, L., Fruchart, J.-C., & Auwerx, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80138-5 · Cited by 303
Retinoic Acid Blocks Adipogenesis by Inhibiting C/EBPβ-Mediated Transcription
Schwarz, E. J., Reginato, M. J., Shao, D., Krakow, S. L., & Lazar, M. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1552 · Cited by 302
Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.049 · Cited by 302
Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation
Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Fur, G. L., & Casellas, P. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.032 · Cited by 298
Massiera, F., Saint-Marc, P., Seydoux, J., Murata, T., Kobayashi, T., Narumiya, S., Guesnet, P., Amri, E.-Z., Negrel, R., & Ailhaud, G. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200346-jlr200 · Cited by 297
Marx, N., Mach, F., Sauty, A., Leung, J. H., Sarafi, M. N., Ransohoff, R. M., Libby, P., Plutzky, J., & Luster, A. D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6503 · Cited by 296
The potential biological mechanisms of arsenic-induced diabetes mellitus
Tseng, C.-H. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.02.009 · Cited by 296
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294
Tamori, Y., Masugi, J., Nishino, N., & Kasuga, M. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2045 · Cited by 294
Corepressors selectively control the transcriptional activity of PPARγ in adipocytes
Guan, H.-P., Ishizuka, T., Chui, P. C., Lehrke, M., & Lazar, M. A. (2005) · Genes & Development · doi:10.1101/gad.1263305 · Cited by 293
Leptin revisited: its mechanism of action and potential for treating diabetes
Coppari, R., & Bjørbæk, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3757 · Cited by 293
Wahli, W., Braissant, O., & Desvergne, B. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90045-4 · Cited by 291
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
Gonzalez, F. J., Peters, J. M., & Cattley, R. C. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.22.1702 · Cited by 290
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286
Nuttall, M. E., & Gimble, J. M. (2000) · Bone · doi:10.1016/s8756-3282(00)00317-3 · Cited by 286
Sanghera, D. K., Ortega, L., Han, S., Singh, J., Ralhan, S. K., Wander, G. S., Mehra, N. K., Mulvihill, J. J., Ferrell, R. E., Nath, S. K., et al. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-59 · Cited by 285
The impact of ethnicity on type 2 diabetes
Abate, N., & Chandalia, M. (2003) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00190-3 · Cited by 284
DiRenzo, J., Söderström, M., Kurokawa, R., Ogliastro, M.-H., Ricote, M., Ingrey, S., Hörlein, A., Rosenfeld, M. G., & Glass, C. K. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.4.2166 · Cited by 284
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Inoue, I., Goto, S.-I., Matsunaga, T., Nakajima, T., Awata, T., Hokari, S., Komoda, T., & Katayama, S. (2001) · Metabolism · doi:10.1053/meta.2001.19415 · Cited by 283
Stress as a neuroinflammatory condition in brain: Damaging and protective mechanisms
García-Bueno, B., Caso, J. R., & Leza, J. C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.001 · Cited by 280
PPARγ and the Treatment of Insulin Resistance
OLEFSKY, J., & SALTIEL, A. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00306-4 · Cited by 279
Reginato, M. J., Krakow, S. L., Bailey, S. T., & Lazar, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.1855 · Cited by 277
APC-dependent suppression of colon carcinogenesis by PPARγ
Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D. W., Bronson, R. T., Edelmann, W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162480299 · Cited by 277
Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
LeBrasseur, N. K., Kelly, M., Tsao, T.-S., Farmer, S. R., Saha, A. K., Ruderman, N. B., & Tomas, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2005 · Cited by 276
Metadata
- Authors
- Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-06
- Volume
- 270
- Issue
- 22
- Pages
- 12953-12956
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2047591801
- Cited by
- 3,625
- References
- 30
- FWCI
- 32.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.